Physician profile
Denaly Chen
NPI 1780188342
$1,346.22
in general payments reported to CMS, 2019-2025
13 companies · $25.70 in 2025
The $25.70 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.17 · 2023: $375 · 2024: $918 · 2025: $25.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257 · Education: $61.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.17 |
| Education | $61.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $334.02 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $204.20 | 2024 | Tagrisso, Enhertu |
| Emd Serono, INC. | $175.67 | 2024 | |
| Merck Sharp & Dohme LLC | $115.82 | 2024-2025 | Welireg, Keytruda |
| Novartis Pharmaceuticals Corporation | $111.72 | 2024 | |
| Celgene Corporation | $102.84 | 2024 | Pomalyst, Reblozyl |
| Pfizer INC. | $97.85 | 2022-2024 | |
| Blueprint Medicines Corporation | $69.39 | 2024 | Ayvakit |
| Genzyme Corporation | $42.28 | 2024 | |
| Genentech USA, INC. | $27.87 | 2024 | Perjeta |
| Eisai INC. | $24.46 | 2024 | |
| Servier Pharmaceuticals LLC | $23.29 | 2024 | |
| Recordati_rare_diseases_inc. | $16.81 | 2024 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denaly Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.